Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -10.58 is 57% above its 5-year average of -24.83, near the high end of its 5-year range (-32.32–-10.58).
51.39% above its 12-month average of -21.77.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.80.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 27 comparable quarters.
EARNINGS PER SHARE (EPS)
-10.58
EARNINGS PER SHARE (EPS) AVG TTM
-21.77
EARNINGS PER SHARE (EPS) AVG 3Y
-25.72
EARNINGS PER SHARE (EPS) AVG 5Y
-24.83
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+51.39%
CURRENT VS 3Y AVG
+58.87%
CURRENT VS 5Y AVG
+57.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NextCure, Inc.
Market Cap
$19.14M
Earnings Per Share (EPS)
-10.58
TTM Avg
-21.77
3Y Avg
-25.72
5Y Avg
-24.83
Market Cap
$18.54M
Earnings Per Share (EPS)
-7.26
TTM Avg
-1.65
3Y Avg
-0.89
5Y Avg
-0.63
Market Cap
$19.66M
Earnings Per Share (EPS)
-32.95
TTM Avg
-46.02
3Y Avg
-111.83
5Y Avg
-112.54
Market Cap
$19.86M
Earnings Per Share (EPS)
-0.89
TTM Avg
-2.16
3Y Avg
-1.83
5Y Avg
-1.83
Market Cap
$18.41M
Earnings Per Share (EPS)
-0.25
TTM Avg
-0.29
3Y Avg
-0.28
5Y Avg
-0.20
Market Cap
$17.63M
Earnings Per Share (EPS)
-0.66
TTM Avg
-0.90
3Y Avg
-9.28
5Y Avg
-9.88
Market Cap
$20.92M
Earnings Per Share (EPS)
-5.65
TTM Avg
-10.30
3Y Avg
-22.40
5Y Avg
-54.48
Market Cap
$17.36M
Earnings Per Share (EPS)
-16.36
TTM Avg
46.76
3Y Avg
-158.09
5Y Avg
-209.03
Market Cap
$17.15M
Earnings Per Share (EPS)
-1.87
TTM Avg
-0.88
3Y Avg
-1.76
5Y Avg
-2.28
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NextCure, Inc. (NXTC) | $19.14M | -10.58 | -21.77 | -25.72 | -24.83 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.54M | -7.26 | -1.65 | -0.89 | -0.63 |
| P3 Health Partners Inc. (PIII)vs › | $19.66M | -32.95 | -46.02 | -111.83 | -112.54 |
| Actuate Therapeutics Inc (ACTU)vs › | $19.86M | -0.89 | -2.16 | -1.83 | -1.83 |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.41M | -0.25 | -0.29 | -0.28 | -0.20 |
| Cosmos Health Inc. (COSM)vs › | $17.63M | -0.66 | -0.90 | -9.28 | -9.88 |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.92M | -5.65 | -10.30 | -22.40 | -54.48 |
| PAVmed Inc. (PAVM)vs › | $17.36M | -16.36 | 46.76 | -158.09 | -209.03 |
| Lipocine Inc. (LPCN)vs › | $17.15M | -1.87 | -0.88 | -1.76 | -2.28 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.13M | -0.48 | -0.99 | -1.87 | -3.18 |
Trailing EPS (TTM)
$-10.58
Forward EPS (Est.)
$-6.34
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -19.65 |
| 2024-12-31 | -23.88 |
| 2023-12-31 | -27.04 |
| 2022-12-31 | -32.32 |
| 2021-12-31 | -30.15 |
| 2020-12-31 | -15.95 |
| 2019-12-31 | -25.79 |
| 2018-12-31 | -12.04 |
| 2017-12-31 | -8.17 |
